

OUR STORY

2008-2009

New Bioanalytical CRO model defined.

2010

Launched customized, fully paperless laboratory environment (ELN).

2011

Opened new fit-for-purpose laboratory facility.

2012-2014

Provided GLP and non-GLP bioanalytical services to biotech, pharma, and animal health sponsors.

2015

Named to Inc. 500 list of fastest growing U.S. private companies. Successful first FDA audit.

2016-2017

ELN upgrade: remains unique state-of-the-art platform. Named to Inc. 500 list of fastest growing U.S. private companies again.

2018-2019

Celebrated 10th anniversary. Successful second FDA audit.

2020

AIT Bioscience is acquired by Nexelis.

LAB EQUIPMENT AND TECHNIQUES

- Thermo Vantage™
- Thermo Quantiva™
- Thermo Q-Exactive™ Plus
- Waters® Acquity UPLC®
- Thermo Ultimate™ 3000
- Meso Scale Discovery (MSD®)
- SPARCL™
- BioTek™ Synergy™ H1 Hybrid
- Wizard2™ RIA
- Beckman Coulter™ Vi-Cell™
- Precellys® Cryolys® Evolution



Staff includes both large and small molecule bioanalysis experts.

ABOUT NEXELIS

With unrivaled expertise in immunology, 5 operating sites in North America and Europe, and a translational offerings services covering the needs of the pharmaceutical industry from the lead selection to the late clinical stage, Nexelis is a leading provider of assay development and advanced laboratory testing services in the infectious, metabolic and oncologic fields. Our versatile team of scientists, working with state of the art technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 100 new molecular entities, including blockbuster vaccines and biologics, anti-viral drugs, immunotherapy, gene and cell therapy products.

INDIANAPOLIS, IN, USA

7840 Innovation Boulevard
Indianapolis, IN 46278
317-715-8800

SEATTLE, WA, USA

GOSSELIES, BELGIUM
LAVAL, CANADA, QC
MARBURG, GERMANY
PORTON DOWN, UK
BEIJING, CHINA